Dr Namir Hassan will be meeting the Oxford Pharmacology Society to discuss his reflections on his career journey to date, his knowledge and experience in large pharma and small biotech, his thoughts on key elements of success and his perspective on growth areas in science. Namir Hassan joined Zelluna Immunotherapy in August 2018 to serve as Chief Scientific Officer and as Chief Executive Officer since Jan 2020. He has over 15 years of biotech and pharma industry experience from target validation through to early phase clinical trials.